Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients (StimobII)

27. januar 2017 oppdatert av: AGIR à Dom

Acute and Medium-term Effects of Neuromuscular Electrical Multisite System (Kneehab®) on Cardiovascular Parameters and Induced Muscle Fatigue in Morbidly Obese Patients: Comparison With the Unidirectional Standard Device

The study was designed to test the following hypotheses:

In patients with severe obesity, a multisite electrostimulation session (m-NMES) will induce higher changes in metabolic, inflammatory and cardiovascular parameters and higher increase in muscle strength during stimulated contractions than conventional unidirectional electrostimulation session (c-NMES).

In patients with severe obesity, a six-weeks m-NMES training program will enhance cardiovascular, metabolic and inflammatory parameters.

Studieoversikt

Detaljert beskrivelse

Background: Physical activity is known to reduce cardiovascular risk as far as even minor change in lifestyle could occur. In obesity, physical activity programs remain challenging due to multifactorial causes related to body mass such as shortness of breath, traumatological pain or psychosocial causes. Although neuromuscular electrical stimulation training is presently ignored in the management of obesity, this technique may be appropriate and useful for muscle deconditioning in these patients. Furthermore, direct effects of electrostimulation training program on vascular function have been previously reported in spinal cord injury and chronic heart disease, suggesting that improvement in cardiovascular function may be expected. While a promising new technique of multisite electrical stimulation (the Kneehab® system) has been recently commercialized, few study have investigated the acute effects of electrostimulation on vascular function and not any study report the effects of electrical stimulation in obese patients.

MAIN OUTCOME OF THE ACUTE PHASE STUDY (1st part):To study the effect of multisite electrical stimulation session (m-NMES) on arterial stiffness as compared to conventional unidirectional electrical stimulation session (c-NMES) in patients with severe obesity. Secondary outcomes of the observational study: 1/ To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as electrically-induced muscle fatigue as compared with c-NMES in patients with morbid obesity. 2/ To study the profile of responders to electrical stimulation according to body composition, 6-minute walking distance, spontaneous physical activity or susceptibility to tolerate electrical stimulation. Response to electrical stimulation will be assessed by an improvement in arterial stiffness after stimulation, if so.

MAIN OUTCOME OF THE INTERVENTIONAL STUDY (2nd part):To study the effect of a multisite electrical stimulation training program (m-NMES) (6 weeks, 30 sessions) on arterial stiffness in patients with severe obesity. Secondary outcomes of the interventional study: To study the effect of m-NMES on endothelial function, blood pressure, systemic inflammation and metabolic status (fasting glucose and insulin) as well as muscle strength, body composition, functional capacity (6-minute walking distance) and spontaneous physical activity, after 15 sessions (3 weeks) and after 30 sessions (6 weeks) of training program. Evaluation of the dose-response to m-NMES training in terms of arterial stiffness and functional capacity.

Expected outcomes: Acute change in arterial stiffness and/or endothelial function is expected after one m-NMES session and/or after c-NMES session. M-NMES session is expected to induce higher changes than c-NMES stimulation session on cardiovascular and muscle parameters. Chronic changes in arterial stiffness and/or endothelial function is expected after 6 weeks of m-NMES training.

Studietype

Intervensjonell

Registrering (Forventet)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female, aged over 18 years
  • Morbid obesity (BMI > 35 kg/m²)
  • Not included into exercise training program in the year prior to inclusion- Spontaneous physical activity lower than 160 min wk (i.e. < 30 min/d x 5 d/wk).

Additional Inclusion criteria for the interventional study:

  • Patients with PWV > 9.3 m / s

Exclusion Criteria:

  • Underage- Pregnant or parturient women
  • Persons deprived of their liberty for judicial or administrative reasons, person under a legal protection measure (article L1121-8)
  • Exclusion period in other studies- Person not affiliated to a social security scheme
  • Chronic alcoholism

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: m-NMES first
Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
Andre navn:
  • Kneehab(R) Stimulator
Annen: c-NMES first
Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
Andre navn:
  • Kneehab(R) Stimulator

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Delta arterial stiffness
Tidsramme: Day1 and Day3
Change in carotid-femoral Pulse wave velocity (PWV) after NMES sessions
Day1 and Day3

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Delta pulse arterial tonus (RH-PAT)
Tidsramme: Day1 and Day3
change in pulse arterial tonometry after NMES sessions
Day1 and Day3
NMES-induced muscle fatigue
Tidsramme: Day1 and Day3
change in maximal voluntary contraction after NMES sessions
Day1 and Day3
Delta blood pressure
Tidsramme: Day1 and Day3
changes in systolic and diastolic blood pressures after NMES sessions
Day1 and Day3
Delta plasmatic biomarkers
Tidsramme: Day1 and Day3
changes in inflammatory and metabolic plasmatic biomarkers after NMES sessions
Day1 and Day3
Body composition
Tidsramme: Day1, Day21 and Day 42
Fat-free mass and fat-free mass indexes assessed by impedancemetry
Day1, Day21 and Day 42
Spontaneous physical activity
Tidsramme: Day1 and Day 42
Number of hours per day of physical activity at 1, 2, 3, 4 or 5 metabolic equivalent(METS),Number of step per day,using a 7-days actigraphy
Day1 and Day 42
Maximal voluntary contraction
Tidsramme: Day1, Day21 and Day 42
Quadriceps peak force
Day1, Day21 and Day 42
Walking distance
Tidsramme: Day1 and Day 42
6-minute-walking test
Day1 and Day 42
Arterial stiffness
Tidsramme: Day1, Day21 and Day 42
Pulse wave velocity (PWV) measurements
Day1, Day21 and Day 42
Pulse artery tone (RH-PAT)
Tidsramme: Day1, Day21 and Day 42
Pulse artery tonometry measurement
Day1, Day21 and Day 42
Plasmatic biomarkers
Tidsramme: Day1, Day21 and Day 42
Inflammatory and metabolic biomarkers
Day1, Day21 and Day 42
Blood pressure
Tidsramme: Day1, Day21 and Day 42
Arterial systolic and diastolic blood pressure
Day1, Day21 and Day 42
Response to m-NMES
Tidsramme: Day42
Delta in current intensity during m-NMES between the first to the last session
Day42

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Jean-Louis Pépin, MD, PhD, Laboratoire EFCR, CHU de Grenoble, 38043, Grenoble, France

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. januar 2013

Primær fullføring (Forventet)

1. november 2017

Studiet fullført (Forventet)

1. desember 2017

Datoer for studieregistrering

Først innsendt

15. januar 2013

Først innsendt som oppfylte QC-kriteriene

26. mars 2013

Først lagt ut (Anslag)

29. mars 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

30. januar 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. januar 2017

Sist bekreftet

1. juli 2016

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 12-AGIR-04

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere